Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection

被引：17

作者：

Artenie, Andreea Adelina ^{[1
,2
]}

Zang, Geng ^{[2
]}

Daniel, Mark ^{[3
,4
]}

Fortier, Emmanuel ^{[2
,5
]}

Jutras-Aswad, Didier ^{[2
,6
]}

Puzhko, Svetlana ^{[7
]}

Bruneau, Julie ^{[2
]}

机构：

[1] Univ Montreal, Sch Publ Hlth, Dept Social & Prevent Med, 7101 Ave Parc, Montreal, PQ H3N 1X9, Canada

[2] CHU Montreal CRCHUM, Res Ctr, 900 St Denis, Montreal, PQ H2X 0A9, Canada

[3] Univ South Australia, Div Hlth Sci, Sch Populat Hlth, GPO Box 2471, Adelaide, SA 5001, Australia

[4] Univ Melbourne, St Vincents Hosp, Dept Med, 29 Regent St, Fitzroy, Vic 3065, Australia

[5] Univ Montreal, Fac Med, Dept Family & Emergency Med, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada

[6] Univ Montreal, Fac Med, Dept Psychiat, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada

[7] McGill Univ, Fac Med, Dept Family Med, 5858 Cote Des Neiges, Montreal, PQ H3S 1Z1, Canada

来源：

INTERNATIONAL JOURNAL OF DRUG POLICY | 2017年 / 47卷

基金：

加拿大健康研究院;

关键词：

People who inject drugs; Injection drug use; HCV; Antiviral treatment; Hepatitis C care; Cohort study; PRIMARY MEDICAL-CARE; QUALITY-OF-LIFE; SERVICE UTILIZATION; PEOPLE; ADDICTION; CESSATION; SEVERITY;

D O I：

10.1016/j.drugpo.2017.05.033

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Background: It is unclear whether treatment and care for hepatitis C virus (HCV) infection can help people who inject drugs (PWID) modify their injection drug use behaviours. This study examined changes in injection drug use among PWID with acute HCV systematically referred for HCV clinical assessment and treatment and offered targeted health care services, over the course of one year. Methods: The study sample included PWID with documented acute HCV infection recruited and followed-up semi-annually at least twice in IMPACT (2007-2015), a longitudinal community-based prospective study in Montreal, Canada. Following enrolment, participants with contra-indications to treatment due to severe co-morbidity were offered targeted health care services. Pegylated interferon alpha (12-24 weeks) was offered to all other participants who did not spontaneously resolve their infection. At each study visit, data were collected on socio-demographic factors and drug use patterns. Logistic regression was used to assess changes in injection drug use at one-year follow-up. Results: Of the 87 eligible participants (mean age: 35.6; 78.2% male), 21.8% received treatment [(RT), Sustained virological response: 84.2%], 25.3% spontaneously resolved their infection (SR), 14.9% had contra-indication(s) (CI) and 37.9% chose not to engage in HCV care post-diagnosis (NE). In multivariate analyses adjusting for age, gender and injection drug use at baseline, the RT [Adjusted odds ratio (AOR): 0.18; 95% Confidence interval (CI): 0.04-0.76], SR (AOR: 0.34; 95% CI: 0.08-1.40), and CI (AOR: 0.24; 95% CI: 0.05-1.22) groups were less likely to report injection drug use at follow-up relative to the NE group. Conclusion: PWID who received treatment, spontaneously resolved their infection or presented with treatment contra-indication(s) reported reduced injection drug use at one-year follow-up relative to those who did not engage in therapy. Findings suggest that the benefits of HCV assessment and treatment may extent to helping PWID modify their injection drug use patterns. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：239 / 243

页数：5

共 17 条

[1] Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C [J].